摘要
目的观察肝动脉化疗栓塞术(TACE)后口服阿帕替尼治疗中晚期肝癌的疗效。方法选取2020年11月—2021年11月在福建省立医院进行治疗的中晚期肝癌患者80例,按照随机数字表法分为常规组与阿帕替尼组,各40例。患者均接受TACE治疗,术后常规组采用常规治疗,阿帕替尼组在常规组基础上口服阿帕替尼,2组均持续治疗3个月。比较2组随访1年无进展生存率,治疗前与治疗3个月后甲胎蛋白(AFP)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)、肝功能指标[总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、白蛋白(Alb)]及不良反应。结果随访1年,阿帕替尼组无进展生存率高于常规组(87.50%vs.27.50%,χ^(2)=29.463,P<0.001)。治疗3个月后,2组血清AFP、VEGF、MMP-9水平低于治疗前,且阿帕替尼组低于常规组(P<0.01);2组血清TBil、ALT水平高于治疗前,血清Alb水平低于治疗前,但阿帕替尼组血清TBil、ALT水平低于常规组,血清Alb水平高于常规组(P<0.05或P<0.01)。阿帕替尼组不良反应总发生率低于常规组(7.50%vs.40.00%,χ^(2)=11.665,P=0.001)。结论TACE后口服阿帕替尼治疗中晚期肝癌可有效抑制肿瘤组织新生血管生成,降低对肝功能的影响,延缓病情进展,提高无进展生存率,且安全性较高。
Objective To observe the clinical efficacy of apatinib oral after TACE in the treatment of middle and advanced liver cancer.Methods A total of 80 patients with middle and advanced liver cancer who treated in Fujian Provincial Hospital from November 2020 to November 2021 were selected,and they were divided into the routine group and the apatinib group by random number table method,40 cases in each group.All patients were received TACE,after operation,patients in the routine group were treated with routine treatment,and patients in the apatinib group were given apatinib oral,both groups were treated for 3 months.Progression-free survival rate followed-up for 1 year,and AFP,VEGF,MMP-9,liver function indexes(TBil,ALT,Alb)before and after 3 months of treatment,and adverse reactions were compared between the two groups.Results Followed-up for 1 year,progression-free survival rate of the apatinib group was higher than that of the routine group(87.50%vs.27.50%,χ^(2)=29.463,P<0.001).After 3 months of treatment,serum AFP,VEGF,and MMP-9 levels in the two groups were lower than those before treatment,and the apatinib group were lower than those of the routine group(P<0.01);Serum TBil and ALT levels in the two groups were higher than those before treatment,serum Alb level was lower than that before treatment,but serum TBil and ALT levels of the apatinib group were lower than those of the routine group,serum Alb level was higher than that of the routine group(P<0.05 or P<0.01).Incidence of adverse reactions in the apatinib group was significantly lower than that in the routine group(7.50%vs.40.00%,χ^(2)=11.665,P=0.001).Conclusion Apatinib oral after TACE can effectively inhibit angiogenesis in tumor tissue of patients with middle and advanced liver cancer,and reduce the impact on liver function,delay the progression of the disease,and promote the progression-free survival rate,and with higher safety.
作者
陈海燕
CHEN Haiyan(Outpatient Western Medicine Drugstore,Fujian Provincial Hospital,Fuzhou 350001,China)
出处
《临床合理用药杂志》
2023年第30期26-28,37,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
中晚期肝癌
肝动脉化疗栓塞术
阿帕替尼
口服
无进展生存
Middle and advanced liver cancer
Hepatic artery chemoembolisation
Apatinib
Oral
Progression-free survival
